Metabolic / body-composition research
Limited Human Evidence
Historical investigation does not equal current approved obesity care.
Also known as Tyr-hGH fragment 177-191
Modified fragment of human growth hormone studied historically for metabolic hypotheses. Not an established approved obesity medicine.
AOD-9604 is a modified fragment of the C-terminal region of human growth hormone, investigated for fat-metabolism hypotheses without intending full GH receptor agonism of intact GH. It is not an FDA-approved obesity drug comparable to semaglutide or tirzepatide. Human evidence remains limited relative to modern incretin medicines.
AOD-9604 is a piece of growth hormone that researchers hoped might affect fat metabolism without all of GH's other actions.
It should not be confused with approved GLP-1 or GIP/GLP-1 medicines, which have large modern trial programs.
AOD-9604 is a snippet of growth hormone studied for possible effects on fat metabolism. It is not the same as taking growth hormone, and it is not an approved modern weight-management drug.
The analog was designed to capture metabolic fragments of hGH while reducing full GH-receptor/IGF-I axis agonism. Whether that design achieved a clinically useful, safe human effect remains insufficiently established compared with approved metabolic drugs.
Step 1
Peptide
AOD-9604 (hGH fragment analog)
Step 2
Proposed target
Metabolic pathways distinct from full GH agonism (hypothesis)
Step 3
Pathway
Experimental lipolysis / body-composition research
Step 4
Observed research effect
Limited/uncertain human evidence; not an approved standard therapy
Historical investigation does not equal current approved obesity care.
Some clinical investigation has occurred historically. A contemporary, labeled benefit-risk profile like Wegovy/Zepbound is not available. Treat claims conservatively.
Fragment-based lipolytic hypotheses exist in older experimental literature.
No sourced study cards have been attached yet. Information not sufficiently established at the study-card level.
Safety information may be incomplete, especially for experimental peptides.
Safety information may be incomplete, especially for experimental peptides. Consult a qualified healthcare professional for personal medical advice.
Long-term safety: Not sufficiently established.
Evidence limitations: Do not analogize trial results from semaglutide or tirzepatide to this fragment.
Administration practices vary by compound and clinical context. Follow approved prescribing information or guidance from a qualified healthcare professional. This page does not provide injection technique, mixing, or personalized dosing instructions.
Discovery
complete
hGH fragment analog design.
Human studies
in progress
Historical clinical investigation; modern approval not established.
Regulatory status
not started
Not an established approved obesity drug here.
No. Different mechanism class and a much weaker, less established evidence and regulatory profile.
Metabolic Research
GLP-1 receptor agonist approved in the United States for specific diabetes and weight-management indications, depending on product and labeling.
View peptide →
Metabolic Research
Dual GIP and GLP-1 receptor agonist approved in the United States for specific diabetes and weight-related indications, depending on product labeling.
View peptide →